Crystagen
Also called EDP; Glu-Asp-Pro
An experimental three-amino-acid bioregulator peptide discussed in immune research. Its findings are specific and early and do not show protection against infections or reversal of immune aging.
Overview
What it is
A tripeptide of glutamic acid, aspartic acid and proline, from the Khavinson research group. It is not a thymus extract.
How it works
A 2014 spleen-aging study described Crystagen as activating B cells, the antibody-producing part of the immune system, but noted it did not renew cells in the aging spleen.
What the research shows
The main human data come from a patent: 38 older adults given the peptide by injection with standard treatment had normalized immune tests in 82% versus 56% of 32 comparison patients. This is inventor-reported, not a peer-reviewed randomized trial, and lab results are not the same as fewer infections.
Studied for
- B-cell activity in aging spleenanimal
- Immune lab tests in older adultspatent report
Safety and regulatory status
Safety and side effects
No dependable side-effect rates, long-term safety or drug interaction data. People with autoimmune disease, a transplant, or on immune-suppressing treatment should not view "immune support" as reassurance.
Regulatory status
Not approved by the FDA for any use.
Common questions
Does Crystagen prevent colds?
That has not been shown.
Is Crystagen a cancer treatment?
No. During cancer treatment, follow your oncology team's infection-prevention plan.
Has it been studied in people?
Only in limited, inventor-reported patent examples.
Related in Energy and Wellness
Sources and further reading (5)
- Khavinson V, et al. Transport of ultrashort peptides using POT and LAT carriers. Int J Mol Sci, 2022.
- Khavinson VK, et al. Peptide substance revealing an immunogeroprotective effect. US8057810B2 (patent).
- Chervyakova NA, et al. Immunoprotective activity of peptides in spleen during aging. Advances in Gerontology, 2014.
- National Cancer Institute. Infection and neutropenia during cancer treatment.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).